Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].

Autor: Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu., Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK., Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia., Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland., Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine., Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan., Tamada S; Bell Land General Hospital, Osaka, Japan., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Perini R; Merck & Co., Inc., Rahway, NJ, USA., Rhoda Molife L; MSD UK, London, UK., Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany., Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Jazyk: angličtina
Zdroj: European urology [Eur Urol] 2023 Nov; Vol. 84 (5), pp. e123-e124. Date of Electronic Publication: 2023 Sep 02.
DOI: 10.1016/j.eururo.2023.08.010
Databáze: MEDLINE